US · BNTX · BIOTECHNOLOGY
BioNTech SE (BNTX) intrinsic value and stock valuation
$80.96as of 2026-11-21 · Mkt cap 23.16B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BioNTech SE DCF and intrinsic value
InvestorsCraft values BNTX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from BNTX’s statements →
BioNTech SE Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Teva Pharmaceutical Industries Limited (TEVA) $39.23
- Natera, Inc. (NTRA) $273.40
- DexCom, Inc. (DXCM) $79.32
- Biogen Inc. (BIIB) $249.59
- Koninklijke Philips N.V. (PHG) $28.61
- Royalty Pharma plc (RPRX) $68.45
- Incyte Corporation (INCY) $114.63
- STERIS plc (STE) $255.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.75B | $3.82B | $17.3B | $19B |
| Operating income | -$-623.87M | -$-1.31B | $690.4M | $12.6B | $15.3B |
| Net income | -$-1.09B | -$-665.3M | $930.3M | $9.43B | $10.3B |
| EPSd | -$-4.51M | -$-2.77M | $3.83M | $37.8M | $39.6M |
| Operating cash flow | $438M | $207.7M | $5.37B | $13.6B | $889.7M |
| Capital expenditure | -$-168.19M | -$-452.3M | -$-705.5M | -$-363.3M | -$-154M |
| Free cash flow | $269.8M | -$-244.6M | $4.67B | $13.2B | $735.7M |
| Total assets | $22B | $22.5B | $23B | $23.3B | $15.8B |
| Total debt | $267.3M | $254.2M | $219.1M | $212.2M | $301.5M |
| Net debt | -$-7.4B | -$-9.51B | -$-11.44B | -$-13.66B | -$-1.39B |
| Total equity | $19.2B | $19.4B | $20.2B | $20.1B | $11.9B |
| Cash and short-term investments | $14.8B | $16.8B | $16.5B | $14.1B | $2.07B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.75B | $3.82B | $17.3B | $19B |
| Cost of revenue | $616.5M | $541.3M | $599.8M | $3B | $2.91B |
| Gross profit | $2.14B | $2.21B | $3.22B | $14.3B | $16.1B |
| Research and development expenses | $2.02B | $2.25B | $1.78B | $1.54B | $949.2M |
| Selling, general and administrative expenses | $698.2M | $599M | $557.7M | $541.2M | $327.2M |
| Other expenses | $44M | $670.9M | $188M | -$-405.3M | -$-495M |
| Operating expenses | $2.76B | $3.52B | $2.53B | $1.67B | $781.4M |
| Cost and expenses | $3.38B | $4.07B | $3.13B | $4.67B | $3.69B |
| Interest income | $252.2M | $0.00 | $351.3M | $47.4M | $1.56M |
| Interest expense | $13.6M | $13.2M | $7.76M | $15.8M | $5.63M |
| Depreciation and amortization | $367.7M | $298M | $183.4M | $123.3M | $75.2M |
| Ebitda | -$-628M | -$-367.1M | $1.38B | $13.1B | $15B |
| Operating income | -$-623.87M | -$-1.31B | $690.4M | $12.6B | $15.3B |
| Total other income/expenses, net | -$-385.46M | $636.6M | $495.7M | $311.4M | -$-237.4M |
| Income before tax | -$-1.01B | -$-677.7M | $1.19B | $13B | $15B |
| Income tax expense | $81.9M | -$-12.4M | $255.8M | $3.52B | $4.75B |
| Net income | -$-1.09B | -$-665.3M | $930.3M | $9.43B | $10.3B |
| Weighted average shares outstanding | $241.7M | $240.4M | $240.6M | $243.3M | $244M |
| Weighted average diluted shares outstanding | $241.7M | $240.4M | $242.7M | $249.8M | $259.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $14.8B | $16.8B | $16.5B | $14.1B | $2.07B |
| Net receivables | $984.5M | $1.52B | $2.34B | $7.15B | $12.4B |
| Inventory | $110.7M | $283.3M | $357.7M | $439.6M | $502.5M |
| Total current assets | $16.1B | $18.8B | $19.5B | $21.9B | $15.1B |
| Property, plant and equipment, net | $1.29B | $1.18B | $971.6M | $821.1M | $520.4M |
| Goodwill and intangible assets | $1.97B | $1.17B | $1.17B | $219.7M | $202.4M |
| Long-term investments | $2.49B | $1.25B | $1.18B | $80.2M | $21.3M |
| Total non-current assets | $5.84B | $3.73B | $3.48B | $1.36B | $758.5M |
| Total assets | $22B | $22.5B | $23B | $23.3B | $15.8B |
| Accounts payable | $534.7M | $426.7M | $354M | $204.1M | $160M |
| Short-term debt | $52.2M | $39.5M | $28.1M | $36M | $129.9M |
| Deferred revenue | $754.6M | $294.9M | $353.3M | $77.1M | $186.1M |
| Total current liabilities | $2.14B | $2.52B | $2.07B | $2.95B | $3.48B |
| Long-term debt | $215.1M | $214.7M | $191M | $176.2M | $171.6M |
| Deferred revenue, non-current | $88M | $183M | $398.5M | $48.4M | $9M |
| Total non-current liabilities | $621.8M | $595.4M | $689.9M | $272.9M | $455.5M |
| Capital lease obligations | $185.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $2.76B | $3.12B | $2.76B | $3.22B | $3.94B |
| Common stock | $258.9M | $248.6M | $248.6M | $248.6M | $246.3M |
| Retained earnings | $18B | $19.1B | $19.8B | $18.8B | $9.88B |
| Accumulated other comprehensive income (loss) | -$-1.46B | -$-1.33B | -$-984.6M | -$-848.9M | $93.9M |
| Total equity | $19.2B | $19.4B | $20.2B | $20.1B | $11.9B |
| Total investments | $9.65B | $8.28B | $6.06B | $269.6M | $402.9M |
| Total debt | $267.3M | $254.2M | $219.1M | $212.2M | $301.5M |
| Net debt | -$-7.4B | -$-9.51B | -$-11.44B | -$-13.66B | -$-1.39B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.09B | -$-677.7M | $1.19B | $13B | $15B |
| Depreciation and amortization | $367.7M | $298M | $183.4M | $123.3M | $75.2M |
| Stock-based compensation | $0.00 | $100.9M | $51.4M | $108.6M | $93.9M |
| Change in working capital | $516.6M | $1.22B | $5.57B | $4.52B | -$-10.73B |
| Accounts receivable | $1.04B | $387.7M | $5.37B | $4.37B | -$-11.81B |
| Inventory | $170.9M | $74.5M | $81.9M | $62.9M | -$-438.4M |
| Accounts payable | -$-695.23M | $758.4M | $118.9M | $85.7M | $1.52B |
| Net cash provided by operating activities | $438M | $207.7M | $5.37B | $13.6B | $889.7M |
| Investments in property, plant and equipment | -$-719.44M | -$-286.5M | -$-250.1M | -$-329.2M | -$-127.5M |
| Acquisitions, net | $183.3M | $0.00 | -$-336.9M | $0.00 | -$-20.8M |
| Net cash used for investing activities | -$-2.37B | -$-2.08B | -$-6.95B | -$-35.3M | -$-566.1M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $110.5M | $160.9M |
| Common stock repurchased | $0.00 | $0.00 | -$-738.5M | -$-986.4M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | -$-484.3M | $0.00 |
| Net cash used for financing activities | -$-50.81M | -$-45.9M | -$-778.6M | -$-1.42B | $94.2M |
| Net change in cash | -$-931.17M | -$-1.9B | -$-2.21B | $12.2B | $482.5M |
| Cash at end of period | $7.67B | $9.76B | $11.7B | $13.9B | $1.69B |
| Operating cash flow | $438M | $207.7M | $5.37B | $13.6B | $889.7M |
| Capital expenditure | -$-168.19M | -$-452.3M | -$-705.5M | -$-363.3M | -$-154M |
| Free cash flow | $269.8M | -$-244.6M | $4.67B | $13.2B | $735.7M |
Line items
Line items
Line items
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- CEO
- Ugur Sahin
- Employees
- 7.81K
- Beta
- 1.32
Explore
Frequently asked questions
What is the intrinsic value of BioNTech SE (BNTX)?
BioNTech SE (BNTX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BNTX undervalued?
BNTX trades at a price of $80.96 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.